Enerzair Breezhaler Europeiska unionen - svenska - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - läkemedel mot obstruktiv lungsjukdom, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Bemrist Breezhaler Europeiska unionen - svenska - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Zimbus Breezhaler Europeiska unionen - svenska - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - läkemedel mot obstruktiv lungsjukdom, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Tabrecta Europeiska unionen - svenska - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, non-small cell lung - antineoplastiska medel - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Locametz Europeiska unionen - svenska - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklid imaging - diagnostiska radioaktiva läkemedel - detta läkemedel är endast för diagnostisk användning. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Herwenda Europeiska unionen - svenska - EMA (European Medicines Agency)

herwenda

sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastiska medel - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Tevimbra Europeiska unionen - svenska - EMA (European Medicines Agency)

tevimbra

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiska medel - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Pluvicto Europeiska unionen - svenska - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostata tumörer, kastrering-resistent - terapeutiska radioaktiva läkemedel - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Lioresal 0,5 mg/ml Injektions-/infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lioresal 0,5 mg/ml injektions-/infusionsvätska, lösning

novartis sverige ab - baklofen - injektions-/infusionsvätska, lösning - 0,5 mg/ml - baklofen 0,5 mg aktiv substans - baklofen

Lioresal 10 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lioresal 10 mg tablett

novartis sverige ab - baklofen - tablett - 10 mg - baklofen 10 mg aktiv substans; vetestärkelse hjälpämne - baklofen